From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapyThe approval of donanemab and lecanemab in the European Union came with a narrower label than the pivotal trials that supported it.Both agents are restricted to patients with early symptomatic Alzheimer's disease (AD) who are apolipoprotein E (APOE) ε4 non-carriers or het-